CAMP4 THERAPEUTICS Ebitda Over Time
| CAMP Stock | USD 4.79 0.10 2.13% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out CAMP4 THERAPEUTICS Performance and CAMP4 THERAPEUTICS Correlation. CAMP4 |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CAMP4 THERAPEUTICS. If investors know CAMP4 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CAMP4 THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CAMP4 THERAPEUTICS is measured differently than its book value, which is the value of CAMP4 that is recorded on the company's balance sheet. Investors also form their own opinion of CAMP4 THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is CAMP4 THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CAMP4 THERAPEUTICS's market value can be influenced by many factors that don't directly affect CAMP4 THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CAMP4 THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if CAMP4 THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CAMP4 THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare CAMP4 THERAPEUTICS and related stocks such as DZS Inc, Harmonic, and CommScope Holding Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HLIT | 4.8 M | 56.1 M | 35.1 M | 22.4 M | 18.2 M | 8.2 M | (18.8 M) | (44.9 M) | 18.7 M | 33.5 M | 999 K | 32.5 M | 65.1 M | 22.2 M | 21.1 M |
| COMM | 474.1 M | 265 M | 552.5 M | 609 M | 786.9 M | 596.4 M | 1 B | 888.6 M | 829.2 M | 737.9 M | 746.6 M | 813 M | 85.3 M | 519.1 M | 702 M |
| NTGR | (170.6 M) | 129.8 M | 129.3 M | 118.4 M | 178.8 M | 92.8 M | 121.9 M | 87.1 M | 45 M | 26.2 M | 94.5 M | 80.5 M | (23.8 M) | (33.3 M) | (31.6 M) |
| CMTL | (600 K) | 69.7 M | 49.8 M | 57.8 M | 40.7 M | 34.2 M | 47.9 M | 56.1 M | 62.4 M | 57.7 M | (37.8 M) | (345 K) | 18.7 M | (44.8 M) | (42.6 M) |
| MYNA | 16.3 K | 16.3 K | 16.3 K | 16.3 K | (152.1 K) | (740.8 K) | (1.7 M) | (6.8 M) | (7.4 M) | (9.7 M) | (17.9 M) | (40.4 M) | (68.2 M) | (71.1 M) | (67.5 M) |
| KN | 230.2 M | 230.2 M | 259 M | 274.4 M | (42.2 M) | (78.8 M) | 135.2 M | 123.4 M | 131.2 M | 139.5 M | 110.5 M | 184.9 M | (360 M) | 98.9 M | 74.2 M |
| ITRN | (6.2 M) | 52.3 M | 46.2 M | 58.7 M | 58.9 M | 52.3 M | 60.5 M | 69.9 M | 76.7 M | 97.5 M | 50.1 M | 69.3 M | 75.5 M | 87.4 M | 49.8 M |
| AVNW | 9.1 M | 3 M | 12.9 M | (31.1 M) | (13.1 M) | (26 M) | 34 K | 2.6 M | 2.4 M | 7.8 M | 27.5 M | 33.4 M | 33.8 M | 28.3 M | 29.7 M |
| FEIM | 7.1 M | 9.2 M | 7.1 M | 7.3 M | 6.6 M | 4 M | (4.8 M) | (10 M) | (15 K) | (7.6 M) | 2.3 M | (7.2 M) | (2.2 M) | 7.7 M | 8.1 M |
| DGII | 2.3 M | 21.5 M | 16.5 M | 8 M | 13.3 M | 23.2 M | 19.3 M | 15.2 M | 10.1 M | 33.4 M | 38.8 M | 72.2 M | 50.1 M | 48.1 M | 26.6 M |
| ADTN | 15.5 M | 208.3 M | 78.1 M | 69.2 M | 68.2 M | 30.2 M | 52.4 M | 56.2 M | (24.2 M) | (16.3 M) | 10.4 M | 9.8 M | 28.8 M | (96.1 M) | (91.3 M) |
| KVHI | 1.1 M | (311 K) | 7.2 M | 7.3 M | 2.6 M | 4.1 M | (534 K) | 2.6 M | (5.9 M) | (19 M) | (10.1 M) | 1.4 M | 10 M | (1.7 M) | (1.6 M) |
| TSAT | 778.6 M | 778.6 M | 778.6 M | 778.6 M | 778.6 M | 778.6 M | 778.6 M | 778.6 M | 778.6 M | 778.6 M | 634.7 M | 626 M | 395.3 M | 1.1 B | 786.3 M |
CAMP4 THERAPEUTICS and related stocks such as DZS Inc, Harmonic, and CommScope Holding Ebitda description
My Equities
My Current Equities and Potential Positions
| CAMP4 THERAPEUTICS PORATION | CAMP |
Specialization | Healthcare, Biotechnology |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.79
Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.